|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Marin JJ, de Medina Sanchez F, Castaño B,
Bujanda L, Romero MR, Martinez-Augustin O, Moral-Avila RD and Briz
O: Chemoprevention, chemotherapy and chemoresistance in colorectal
cancer. Drug Metab Rev. 44:148–172. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wiela-Hojeńska A, Kowalska T,
Filipczyk-Cisarz E, Łapiński Ł and Nartowski K: Evaluation of the
toxicity of anticancer chemotherapy in patients with colon cancer.
Adv Clin Exp Med. 24:103–111. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nawa A, Tanino T, Luo C, Iwaki M, Kajiyama
H, Shibata K, Yamamoto E, Ino K, Nishiyama Y and Kikkawa F: Gene
directed enzyme prodrug therapy for ovarian cancer: Could GDEPT
become a promising treatment against ovarian cancer? Anticancer
Agents Med Chem. 8:232–239. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hedley D, Ogilvie L and Springer C:
Carboxypeptidase-G2-based gene-directed enzyme-prodrug therapy: A
new weapon in the GDEPT armoury. Nat Rev Cancer. 7:870–879. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Karjoo Z, Chen X and Hatefi A: Progress
and problems with the use of suicide genes for targeted cancer
therapy. Adv Drug Deliv Rev. 99:113–128. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nouri FS, Wang X and Hatefi A: Genetically
engineered theranostic mesenchymal stem cells for the evaluation of
the anticancer efficacy of enzyme/prodrug systems. J Control
Release. 200:179–187. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zu B, Shi Y, Xu M, You G, Huang Z, Gao M
and Feng W: ARE/SUZ12 dual specifically-regulated adenoviral TK/GCV
system for CML blast crisis cells. J Exp Clin Cancer Res.
34:562015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rainov NG: A phase III clinical evaluation
of herpes simplex virus type 1 thymidine kinase and ganciclovir
gene therapy as an adjuvant to surgical resection and radiation in
adults with previously untreated glioblastoma multiforme. Hum Gene
Ther. 11:2389–2401. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chai LP, Wang ZF, Liang WY, Chen L, Chen
D, Wang AX and Zhang ZQ: In vitro and in vivo effect of 5-FC
combined gene therapy with TNF-alpha and CD suicide gene on human
laryngeal carcinoma cell line Hep-2. PLoS One. 8:e611362013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Huang Q, Xia Z, You Y and Pu P: Wild Type
p53 gene sensitizes rat C6 glioma cells to HSV-TK/ACV treatment in
vitro and in vivo. Pathol Oncol Res. 16:509–514. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Park SY, Lee W, Lee J and Kim IS:
Combination gene therapy using multidrug resistance (MDR1) gene
shRNA and herpes simplex virus-thymidine kinase. Cancer Lett.
261:205–214. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Altieri DC: Survivin-The inconvenient IAP.
Semin Cell Dev Biol. 39:91–96. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu JL, Gao W, Kang QM, Zhang XJ and Yang
SG: Prognostic value of survivin in patients with gastric cancer: A
systematic review with meta-analysis. PLoS One. 8:e719302013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xia H, Chen S, Huang H and Ma H: Survivin
over-expression is correlated with a poor prognosis in esophageal
cancer patients. Clin Chim Acta. 446:82–85. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Krieg A, Werner TA, Verde PE, Stoecklein
NH and Knoefel WT: Prognostic and clinicopathological significance
of survivin in colorectal cancer: A meta-analysis. PLoS One.
8:e653382013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Huang J, Lyu H, Wang J and Liu B:
Influence of survivin-targeted therapy on chemosensitivity in the
treatment of acute myeloid leukemia. Cancer Lett. 366:160–172.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jaiswal PK, Goel A and Mittal RD:
Survivin: A molecular biomarker in cancer. Indian J Med Res.
141:389–397. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liao Y and Tang L: Inducible RNAi system
and its application in novel therapeutics. Crit Rev Biotechnol.
36:630–638. 2016.PubMed/NCBI
|
|
20
|
Liu W, Zhu F, Jiang Y, Sun D, Yang B and
Yan H: siRNA targeting survivin inhibits the growth and enhances
the chemosensitivity of hepatocellular carcinoma cells. Oncol Rep.
29:1183–1188. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Takakura M, Kyo S, Kanaya T, Hirano H,
Takeda J, Yutsudo M and Inoue M: Cloning of human telomerase
catalytic subunit (hTERT) gene promoter and identification of
proximal core promoter sequences essential for transcriptional
activation in immortalized and cancer cells. Cancer Res.
59:551–557. 1999.PubMed/NCBI
|
|
22
|
Liu T, Tang A, Zhang G, Chen Y, Zhang J,
Peng S and Cai Z: Calcium phosphate nanoparticles as a novel
nonviral vector for efficient transfection of DNA in cancer gene
therapy. Cancer Biother Radiopharm. 20:141–149. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Libutti SK: New horizons for cancer gene
therapy. Cancer Gene Ther. 21:12014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Backman V and Roy HK: Advances in
biophotonics detection of field carcinogenesis for colon cancer
risk stratification. J Cancer. 4:251–261. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu T, Ye L, He Y, Chen X, Peng J, Zhang
X, Yi H, Peng F and Leng A: Combination gene therapy using
VEGF-shRNA and fusion suicide gene yCDglyTK inhibits gastric
carcinoma growth. Exp Mol Pathol. 91:745–752. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Long H, Li Q, Wang Y, Li Q, Liu T and Peng
J: Effective combination gene therapy using CEACAM6-shRNA and the
fusion suicide gene yCDglyTK for pancreatic carcinoma in vitro. Exp
Ther Med. 5:155–161. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li J, Zhang G, Liu T, Gu H, Yan L and Chen
B: Construction of a novel vector expressing the fusion suicide
gene yCDglyTK and hTERT-shRNA and its antitumor effects. Exp Ther
Med. 4:442–448. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Paíno T, Gangoso E, Medina JM and
Tabernero A: Inhibition of ATP-sensitive potassium channels
increases HSV-tk/GCV bystander effect in U373 human glioma cells by
enhancing gap junctional intercellular communication.
Neuropharmacology. 59:480–491. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang G, Liu T, Chen YH, Chen Y, Xu M,
Peng J, Yu S, Yuan J and Zhang X: Tissue specific cytotoxicity of
colon cancer cells mediated by nanoparticle-delivered suicide gene
in vitro and in vivo. Clin Cancer Res. 15:201–207. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Niu J, Xing C, Yan C, Liu H, Cui Y, Peng
H, Chen Y, Li D, Jiang C, Li N and Yang H: Lentivirus-mediated
CD/TK fusion gene transfection neural stem cell therapy for C6
glioblastoma. Tumour Biol. 34:3731–3741. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Stiksma J, Grootendorst DC and van der
Linden PW: CA 19-9 as a marker in addition to CEA to monitor
colorectal cancer. Clin Colorectal Cancer. 13:239–244. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Glybochko PV, Zezerov EG, Glukhov AI,
Alyaev YG, Severin SE, Polyakovsky KA, Varshavsky VA, Severin ES
and Vinarov AZ: Telomerase as a tumor marker in diagnosis of
prostatic intraepithelial neoplasia and prostate cancer. Prostate.
74:1043–1051. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Crees Z, Girard J, Rios Z, Botting GM,
Harrington K, Shearrow C, Wojdyla L, Stone AL, Uppada SB, Devito JT
and Puri N: Oligonucleotides and G-quadruplex stabilizers:
Targeting telomeres and telomerase in cancer therapy. Curr Pharm
Des. 20:6422–6437. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ayiomamitis GD, Notas G, Zaravinos A,
Zizi-Sermpetzoglou A, Georgiadou M, Sfakianaki O and Kouroumallis
E: Differences in telomerase activity between colon and rectal
cancer. Can J Surg. 57:199–208. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Liu L, Wu W, Zhu G, Liu L, Guan G, Li X,
Jin N and Chi B: Therapeutic efficacy of an hTERT promoter-driven
oncolytic adenovirus that expresses apoptin in gastric carcinoma.
Int J Mol Med. 30:747–754. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Song Y, Xin X, Zhai X, Xia Z and Shen K:
Sequential combination therapy with flavopiridol and autocatalytic
caspase-3 driven by amplified hTERT promoter synergistically
suppresses human ovarian carcinoma growth in vitro and in mice. J
Ovarian Res. 7:1212014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Tian D, Sun Y, Yang Y, Lei M, Ding N and
Han R: Human telomerase reverse-transcriptase promoter-controlled
and herpes simplex virus thymidine kinase-armed adenoviruses for
renal cell carcinoma treatment. Onco Targets Ther. 6:419–426.
2013.PubMed/NCBI
|
|
38
|
Cheung CH, Huang CC, Tsai FY, Lee JY,
Cheng SM, Chang YC, Huang YC, Chen SH and Chang JY:
Survivin-biology and potential as a therapeutic target in oncology.
Onco Targets Ther. 6:1453–1462. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Li Y, Zhou Y, Zheng J, Niu C, Liu B, Wang
M, Fang H and Hou C: Downregulation of survivin inhibits
proliferation and migration of human gastric carcinoma cells. Int J
Clin Exp Pathol. 8:1731–1736. 2015.PubMed/NCBI
|
|
40
|
Mobahat M, Narendran A and Riabowol K:
Survivin as a preferential target for cancer therapy. Int J Mol
Sci. 15:2494–2516. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Altieri DC: Targeting survivin in cancer.
Cancer Lett. 332:225–228. 2013. View Article : Google Scholar : PubMed/NCBI
|
